Alkermes plc Stock News

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index wa

Alkermes Plc (NASDAQ:ALKS) SVP Michael J. Landine sold 25,000 shares of the business’s stock in a transaction dated Tuesday, March 24th. The shares were sold at an average price of $13.91, for a tot

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted

Asset Management One Co. Ltd. trimmed its holdings in Alkermes Plc (NASDAQ:ALKS) by 79.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund own

Alkermes Plc (NASDAQ:ALKS) SVP Michael J. Landine sold 25,000 shares of Alkermes stock in a transaction that occurred on Tuesday, March 24th. The shares were sold at an average price of $13.91, for a

Alkermes Plc (NASDAQ:ALKS) CEO Richard F. Pops sold 75,000 shares of Alkermes stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $14.36, for a to

We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was

The biotechnology industry is comprised of hundreds of companies that fuse biology and technology to develop drugs and related products for the treatment of diseases and medical conditions. Today's bi

Amalgamated Bank raised its stake in shares of Alkermes Plc (NASDAQ:ALKS) by 9.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Com

Onconova Therapeutics (NASDAQ:ONTX) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividen

Urovant Sciences (Nasdaq: UROV) today announced the appointment of accomplished industry veteran Jim Robinson to the position of President and Chief Executive Officer. Mr. Robinson will continue his s

Merrill Lynch analyst Jason Gerberry maintained a Hold rating on Alkermes (ALKS) today and set a price target of $17.00. The company's shares closed last

Merrill Lynch analyst Jason Gerberry maintained a Hold rating on Alkermes (ALKS – Research Report) today and set a price